{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["62(11)"],"submitter":["Barriteau CM"],"pubmed_abstract":["<h4>Background</h4>We instituted RHD genotyping in our transfusion service for obstetrical patients and transfusion candidates. We sought to examine how RHD genotyping resolved weak or discrepant automated microplate direct agglutination (MDA) RhD phenotypings and impacted needs for Rh Immune Globulin (RhIG) and D-negative RBCs.<h4>Study design and methods</h4>We investigated RhD phenotypes with equivocal or reagent-discrepant automated MDA (Immucor, Norcross, GA), weak-2+ immediate-spin tube typings, historically discrepant RhD typings, or D+ typings with anti-D. We performed microarray RHD genotyping (RHD BeadChip, Immucor BioArray Solutions, Warren, NJ). Patients were managed as D+ with weak-D types 1, 2, and 3, and as D-negative with all other results.<h4>Results</h4>Our weak-D prevale"],"journal":["Transfusion"],"pagination":["2194-2199"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9828470"],"repository":["biostudies-literature"],"pubmed_title":["RHD genotyping to resolve weak and discrepant RhD patient phenotypes."],"pmcid":["PMC9828470"],"pubmed_authors":["Ramsey G","Lindholm PF","Sumugod RD","Barriteau CM","Hartman K"],"additional_accession":[]},"is_claimable":false,"name":"RHD genotyping to resolve weak and discrepant RhD patient phenotypes.","description":"<h4>Background</h4>We instituted RHD genotyping in our transfusion service for obstetrical patients and transfusion candidates. We sought to examine how RHD genotyping resolved weak or discrepant automated microplate direct agglutination (MDA) RhD phenotypings and impacted needs for Rh Immune Globulin (RhIG) and D-negative RBCs.<h4>Study design and methods</h4>We investigated RhD phenotypes with equivocal or reagent-discrepant automated MDA (Immucor, Norcross, GA), weak-2+ immediate-spin tube typings, historically discrepant RhD typings, or D+ typings with anti-D. We performed microarray RHD genotyping (RHD BeadChip, Immucor BioArray Solutions, Warren, NJ). Patients were managed as D+ with weak-D types 1, 2, and 3, and as D-negative with all other results.<h4>Results</h4>Our weak-D prevale","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-04T09:30:38.351Z","creation":"2025-04-04T09:30:38.351Z"},"accession":"S-EPMC9828470","cross_references":{"pubmed":["36218305"],"doi":["10.1111/trf.17145"]}}